XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS
12 Months Ended
Dec. 31, 2021
GOODWILL AND INTANGIBLE ASSETS  
GOODWILL AND INTANGIBLE ASSETS

NOTE 8 - GOODWILL AND INTANGIBLE ASSETS

 

The Company incurred $0.08 million and $0.02 million of legal patent costs that were capitalized during the year ended December 31, 2021 and 2020, respectively. During the year ended December 31, 2021, the Company did not acquire any intangibles through an acquisition. During the year ended December 31, 2020, the Company acquired from Sera Labs customer relationships at a fair value of $7.1 million, $2.6 million in Tradename intangibles, $0.5 million in non-compete and $4.7 million in Goodwill from the acquisition of Sera Labs.

 

Intangible Asset Summary

 

As of December 31, 2021 and 2020, goodwill and intangible assets, net, consisted of the following (in thousands):

 

 

 

2021

 

 

2020

 

Goodwill (1)

 

$13,868

 

 

$13,868

 

 

 

 

 

 

 

 

 

 

Intangible assets:

 

 

 

 

 

 

 

 

Acquired IPR&D – Chemistry (2)

 

$502

 

 

$14,460

 

 Pending patents – Cure Pharmaceutical

 

 

341

 

 

 

259

 

Intangible assets subject to amortization:

 

 

 

 

 

 

 

 

 Acquired IPR&D – Chemistry (2)

 

 

13,958

 

 

 

-

 

 Customer relationships (2)

 

 

7,110

 

 

 

7,110

 

 Tradename (2)

 

 

2,610

 

 

 

2,610

 

 Noncompete (2)

 

 

462

 

 

 

462

 

 Intellectual property

 

 

972

 

 

 

972

 

Issued patents

 

 

1,034

 

 

 

1,044

 

Total intangible assets

 

 

26,989

 

 

 

26,917

 

Accumulated amortization

 

 

(4,701 )

 

 

(1,312 )

Intangible assets, net

 

$22,288

 

 

$25,605

 

________ 

(1)

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired from CHI and Sera Labs (see Note 20).

 

 

(2)

See Note 20 for information on the Mergers which were consummated in May 2019 and October 2020. During the year ended December 31, 2021, the Company completed two research and development projects that resulted in the company reclass approximately $13.9 million of IPR&D from intangibles not subject to amortization to intangibles subject to amortization.

Amortization expense was $3.4 million and $0.7 million for the years ended December 31, 2021 and 2020, respectively.

 

The estimated aggregate amortization expense over each of the next five years is as follows (in thousands):

 

2022

 

$3,765

 

2023

 

 

3,592

 

2024

 

 

3,429

 

2025

 

 

2,583

 

2026

 

 

1,517

 

Thereafter

 

 

6,559

 

Total Amortization

 

$21,445